Thalidomide upper limb embryopathy - pathogenesis, past and present management and future considerations
- PMID: 37226469
- PMCID: PMC10466950
- DOI: 10.1177/17531934231177425
Thalidomide upper limb embryopathy - pathogenesis, past and present management and future considerations
Abstract
This review article provides a comprehensive overview of thalidomide upper limb embryopathy including updates about its pathogenesis, a historical account of the management of the paediatric thalidomide patient, experience with management of the adult patient, as well as creating awareness about early onset age-related changes associated with limb differences. Despite its withdrawal from the market in November 1961, novel discoveries have meant thalidomide is licensed again and currently still in use to treat a variety of conditions, including inflammatory disorders and some cancers. Yet, if not used safely, thalidomide still has the potential to cause damage to the embryo. Recent work identifying thalidomide analogues that retain clinical benefits yet without the harmful effects are showing great promise. Understanding the problems thalidomide survivors face as they age can allow surgeons to support their unique healthcare issues and translate these principles of care to other congenital upper limb differences.
Keywords: Thalidomide; cereblon; embryopathy; radial dysplasia; reversed shoulder.
Conflict of interest statement
The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
Figures
References
-
- Asatsuma-Okumura T, Ando H, Simone MD, et al. P63 is a cereblon substrate involved in thalidomide teratogenicity. Nat Chem Biol. 2019, 15: 1077–84. - PubMed
-
- Bauer KS, Dixon SC, Figg WD. Inhibition of angiogenesis by thalidomide requires metabolic activation, which is species-dependent. Biochem Pharmacol. 1998, 55: 1827–34. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
